Tvaster Genkalp is Co-founded in 2021 by Dr Srikar Raman and K Sreedurgalakshmi. Tvaster is transforming molecular diagnostics and precision oncology through advanced epigenetic screening technologies. The startup develops proprietary, high-accuracy genetic solutions, setting a new benchmark in non-invasive cancer detection.
Tvaster Genkalp, a molecular diagnostics startup, has raised $1.25 million in a pre-Series A funding round led by Ideaspring Capital. Existing investors Invigo Softwares and Prof. Mohamed Rela, a globally renowned liver transplant surgeon, also participated in the round. The startup will use the fresh investment to accelerate the expansion and commercialization of Episcreen Liver, a pioneering methylation-based liquid biopsy test for early liver cancer detection. Liver cancer is a rapidly growing global health concern, with over 900,000 new cases annually. Dr Srikar Raman, Co-founder of Tvaster Genkalp, said, "The funding will accelerate nationwide deployment of Episcreen Liver, offering a non-invasive, highly accurate diagnostic alternative for Hepatocellular Carcinoma (HCC), the most common form of liver cancer." He further added that while Alpha-Fetoprotein (AFP), the current standard for HCC screening, has 50% sensitivity, Episcreen Liver achieves 90% sensitivity, thus significantly improving early detection and increasing survival chances by over 70%.
In India, one in five adults suffers from Chronic Liver Disease (CLD) due to Fatty Liver Disease, Hepatitis B & C, Alcohol-related CLD, and other metabolic disorders. However, the current diagnostics remain inadequate, reinforcing the need for high-accuracy, non-invasive alternatives. K. Sreedurgalakshmi, Co-founder of Tvaster Genkalp, added, "True healthcare innovation lies in making a meaningful impact, transforming lives beyond technological advancements. Tvaster's mission is to push the boundaries of genetic research and deliver life-saving solutions to those in need. Fundraise marks a pivotal step in transforming cancer detection and improving patient outcomes. Tvaster is also advancing its oncology diagnostics pipeline with Episcreen Bile, a novel test for Cholangiocarcinoma, an aggressive bile duct cancer with limited early detection options. Additionally, the startup has developed Episcreen HBResist, a chemotherapy resistance test for pediatric hepatoblastoma, addressing a critical gap in childhood cancer treatment. It is focused on achieving significant growth and strengthening R&D efforts. "We see immense potential in Tvaster's approach, not just for initial diagnosis but also for monitoring recurrence in patients undergoing treatment. Their liquid biopsy test, Episcreen Liver, has been developed and validated using over 600 patient samples, achieving 90% sensitivity and specificity for detecting hepatocellular carcinoma (HCC). Early detection can significantly improve survival rates and ensure patients receive curative treatment early on. Ideaspring is very excited to partner with Srikar and Durga scale Tvaster," said Naganand Doraiswany, MD at Ideaspring Capital.